Regulus Therapeutics Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 11 of 11 Posts
Regulus Therapeutics Dips After Warning Of Drug Development Delays
Article By: The Fly Wednesday, November 2, 2016 4:49 PM EDT
Shares of Regulus Therapeutics fell Wednesday after the company reported third-quarter results, which included news of several delays in its drug development efforts.
In this article: RGLS
Read
E Regulus Therapeutics Receives FDA Clinical Hold For Hepatitis C Drug
Article By: Terry Chrisomalis Monday, June 27, 2016 11:35 PM EDT
Shares of Regulus Therapeutics tanked by 60% after the company announced that the FDA has placed a clinical hold on its Hepatitis C drug candidate.
In this article: RGLS
Read
E Regulus Receives Final Milestone Payment From Biogen For Multiple Sclerosis Development
Article By: Terry Chrisomalis Wednesday, October 28, 2015 1:46 PM EDT
Today Regulus Therapeutics (RGLS) announced that it has received its fourth and final milestone payment from Biogen (BIIB).
In this article: RGLS, BIIB
Read
Morning Call For April 8, 2015
Article By: Jim Van Meerten Wednesday, April 8, 2015 8:53 AM EDT
June E-mini S&Ps this morning are little changed as the market awaits today's FOMC meeting minutes. The Euro Stoxx 50 index is down -0.39% after yesterday's rally.
In this article: RAD, DIS, KMI, NRZ, PLAY, RGLS, AZN, OHRP, PNR
Read
Regulus And AstraZeneca To Advance Big Potential NASH Drug
Article By: Terry Chrisomalis Tuesday, April 7, 2015 7:24 PM EDT
AstraZeneca okays go-ahead for microRNA therapeutics in additional area.
In this article: RGLS, AZN, ICPT, CNAT, LJPC
Read
Regulus Therapeutics Announces Final Phase 1 Results For Hepatitis C Study Using RG-101
Article By: Terry Chrisomalis Tuesday, February 10, 2015 5:43 PM EDT
Regulus shares remained negative on announcement of Final Phase 1 Results for RG-101 in Hep C but have reversed course since.
In this article: RGLS
Read
Provectus Biopharmaceuticals Concludes FDA Meeting For PV-10 Phase 3; Successful Completion Of AB Science's Futility Test For Masitinib
Article By: BioMedReports Tuesday, February 10, 2015 5:59 AM EDT
Here is a look at some of the headlines for companies that made news in the healthcare sector on February 9, 2015.
In this article: ACHN, AKBS, AKR.L, AVXL, BIOC, BMRN, BSDM, CLDX, CBMG, CEMI, ENSG, GALE, ICUI, ISLT, IART, JUNO, LJPC, LFVN, MJNA, HTGC, NSPH, OREX, RDHL.TA, RCPT, RGLS, RNN, SBRA, WMGI, VBLT
Read
E Shares Of Prosensa Surge 50% After Announcing It Will Be Acquired By Biomarin
Article By: Terry Chrisomalis Monday, November 24, 2014 10:33 AM EDT
Biomarin is purchasing Prosensa for approximately $840 million.
In this article: BMRN, RNA, SRPT, RGLS
Read
E Rxi Pharmaceuticals Offers Great Risk-Reward Scenario Before Major Catalysts
Article By: Terry Chrisomalis Friday, November 14, 2014 11:05 AM EDT
Rxi Pharmaceuticals is extremely undervalued should approaching catalysts fulfill promise.
In this article: TKMR, RXII, RGLS
Read
E Regulus Therapeutics Continues Its Uptrend After Positive Data In Early Hepatitis C Study
Article By: Terry Chrisomalis Friday, October 24, 2014 2:19 PM EDT
Shares of Regulus Therapeutics (RGLS) soared as much as 100% in one trading session after the company released some early data for their Hepatitis C drug.
In this article: RGLS
Read
Active Stocks: Amgen, Alkermes, Nanosphere, Biogen Idec, Regulus Therapeutics
Article By: BioMedReports Wednesday, October 22, 2014 5:42 PM EDT
U.S. stocks turned lower in afternoon trading on Wednesday, with major indexes erasing earlier gains as a shooting at the Canadian parliament unnerved investors and Boeing and Biogen sold off following results.
In this article: NSPH, ALKS, AMGN, BIIB, RGLS
Read
1 to 11 of 11 Posts